ICD-10 Code for Prostate Cancer: Complete Coding Guide

Accurate prostate cancer coding starts with knowing the patient’s diagnosis, treatment status and medical history. While C61 is the ICD‑10 code for prostate cancer not every encounter with prostate cancer needs the exact same diagnosis code. A patient in treatment a patient with metastatic prostate cancer and a patient who survived prostate cancer and comes for a routine follow‑up may each need a distinct coding method.

These prostate cancer distinctions matter for healthcare providers. Using a diagnosis for prostate cancer missing secondary cancers or putting treatment codes in the wrong order can lead to claim mistakes and needless paperwork.

This guide shows the ICD‑10‑CM codes for prostate cancer how to use them correctly what paperwork is needed and practical billing tips, under the FY2027 ICD‑10‑CM rules that start on October 1  2026 and end on September 30  2027.

What Is the ICD-10 Code for Prostate Cancer?

The ICD-10-CM code, for prostate cancer is C61 – neoplasm of prostate. Doctors and nurses write the code C61 when they record a tumor that starts in the prostate gland.

C61 is part of Chapter 2 of ICD-10-CM a section that lists all neoplasms. The code C61 is used for malignant prostate cancer, especially for prostate adenocarcinoma, which is the most common type.

Although C61 is a billable diagnosis code, accurate coding may require additional codes to describe metastatic involvement, hormone sensitivity, or the purpose of a treatment encounter.

When Should Healthcare Providers Use ICD-10 Code C61?

Providers should report C61 when the medical record supports an established, current primary malignancy of the prostate.

1. Newly Diagnosed Prostate Cancer

When a biopsy shows prostate cancer and the doctor writes down the diagnosis C61 is the code for the main cancer.

For example a urologist sees a patient. The biopsy comes back with adenocarcinoma of the prostate. The doctor goes over treatment choices. Makes a plan. In this case C61 is the code for the current prostate cancer diagnosis.

But here’s the thing. A high PSA number or a weird imaging result does not mean prostate cancer for sure. Coders working in outpatient settings must not use C61 just because the diagnosis is not confirmed. They need a diagnosis, from a biopsy or other confirmed test.

2. Prostate Cancer Under Active Treatment

C61 generally remains appropriate while the patient receives treatment directed at the primary prostate malignancy.

Depending on the clinical situation, treatment may include:

• Radical prostatectomy

• Radiation therapy

• Androgen deprivation therapy

• Systemic anticancer medications

• Other treatments directed at the malignancy

The treatment being delivered does not automatically determine which diagnosis appears first on the claim. Providers and billing teams must also consider the reason for the encounter and applicable sequencing instructions.

3. Prostate Cancer Under Active Surveillance

Some patients who have prostate cancer that’s in one area and is not very likely to spread choose to have active monitoring instead of getting surgery or radiation right away.

Active monitoring does not mean the cancer is gone. The person still has a cancer that has been confirmed and doctors keep checking how the disease is changing using tests blood work called PSA testing, scans and biopsies.

So C61 is usually still the choice, during active monitoring because the cancer is still there.

Active Prostate Cancer vs. Personal History: C61 and Z85.46

Distinguishing cancer from a personal history of cancer is one of the most important decisions, in prostate cancer coding.

Healthcare providers should not automatically continue reporting C61 just because a patient received prostate cancer treatment in the past.

ICD-10 Code C61: Current Prostate Cancer

Use C61 when the primary prostate malignancy remains current, including situations where treatment continues to target the primary cancer.

For instance, a patient undergoes prostatectomy and subsequently receives radiation directed at the original prostate cancer site. The primary malignancy code may remain applicable while that treatment continues, even after removal of the prostate.

ICD-10 Code Z85.46: Personal History of Prostate Cancer

Z85.46 identifies a personal history of malignant neoplasm of the prostate.

The official coding guidelines say that a history code is suitable when the main cancer has been removed or killed when no treatment is planned for that spot and when doctors see no sign of the main cancer left behind.

Think about a patient who finished prostate cancer treatment years back. The doctor writes that there is no cancer and the patient comes for a normal check‑up to watch for cancer.

In this case Z85.46 can be used, together with the follow‑up visit code that fits.

Important: A surgery, by itself does not turn C61 into Z85.46 automatically. Coders must look at leftover disease, any continuing treatment and what the doctor has written.

C61 vs. Z85.46: Quick Comparison

ICD-10 Codes for Metastatic Prostate Cancer

Prostate cancer can spread beyond the prostate gland. It often travels to the bones and to lymph nodes. When doctors confirm that prostate cancer has spread coders must report the disease sites. They should not report the primary cancer.

The ICD-10-CM system makes a difference, between a primary malignant tumor and a secondary malignant neoplasm.

Bone Metastases: ICD-10 Code C79.51

C79.51 – Secondary malignant neoplasm of bone refers to cancer that has moved to the bone.

For example a doctor records prostate cancer that has spread to the lower back and pelvis. The medical record might include C61 and C79.51 depending on why the patient’s being seen.

If the treatment is focused directly on the cancer that has spread to the bone then the secondary cancer may be listed first.

Lymph Node Metastases

Prostate cancer can also involve regional or distant lymph nodes. The correct code depends on the documented location.

The fact that there are lymph nodes doesn’t mean someone has cancer that has spread. Doctors need to write down what they think the problem is. Coders should not decide on their own that something seen on a scan means the cancer has spread.

Other Sites of Metastatic Prostate Cancer

Additional codes may apply when clinicians document metastases at other anatomical sites.

For lung metastases use a specific right-lung or left-lung code if the medical documentation clearly supports it.

Also coders must carefully separate cancer that spreads directly into tissues from cancer that has moved to a different area. These two situations often need coding approaches.

The reason, for the patient’s visit will decide whether the primary cancer or the secondary cancer is listed first. This choice depends on the purpose of the encounter.

ICD-10 Codes for Hormone-Sensitive and Castration-Resistant Prostate Cancer

Hormone sensitivity plays an important role in prostate cancer management. Some tumors respond to treatments that reduce androgen activity, while others progress despite efforts to suppress testosterone.

ICD-10-CM provides additional status codes to distinguish these conditions when the documentation supports them.

Z19.1 – Hormone-Sensitive Malignancy Status

Z19.1 identifies hormone-sensitive malignancy status.

A clinician may document that a patient’s prostate cancer remains responsive to androgen deprivation therapy. In this situation, Z19.1 may supplement C61 when appropriate.

Z19.2 – Hormone-Resistant Malignancy Status

Z19.2 identifies hormone-resistant malignancy status.

This code may apply when the oncologist documents castration-resistant prostate cancer (CRPC). Castration-resistant disease can occur with or without detectable metastases.

Providers should clearly record the disease status rather than relying only on medication history, testosterone levels, or PSA changes.

The Z19 codes serve as additional status codes. They do not replace the underlying malignancy diagnosis.

ICD-10 Codes for Prostate Cancer Treatment Encounters

Not every appointment involving prostate cancer should have C61 as the first-listed diagnosis.

The reason for the visit determines which code takes priority, particularly when the patient attends an encounter specifically to receive cancer treatment.

Chemotherapy – Z51.11

Z51.11 – Encounter for antineoplastic chemotherapy applies when the encounter chiefly involves chemotherapy administration.

For example, a patient with prostate cancer visits an oncology infusion center specifically for a scheduled chemotherapy session. Z51.11 generally appears first, followed by the appropriate malignancy code.

Radiation Therapy – Z51.0

Z51.0 – Encounter for antineoplastic radiation therapy identifies encounters chiefly for external beam radiation treatment.

However, brachytherapy involving radioactive element insertion or implantation follows different sequencing guidance. In those encounters, the malignancy code is generally first-listed rather than Z51.0.

Immunotherapy – Z51.12

Z51.12 – Encounter for antineoplastic immunotherapy applies to qualifying immunotherapy administration encounters.

Importantly, providers should not classify every cancer medication as chemotherapy or immunotherapy. Hormonal treatments, targeted therapies, and other medications may require a different coding approach based on the drug, treatment purpose, and applicable instructions.

These distinctions follow the FY2027 ICD-10-CM neoplasm coding guidelines.

Elevated PSA and Rising PSA: Which ICD-10 Code Applies?

Prostate-specific antigen (PSA) testing helps clinicians evaluate prostate-related conditions and monitor patients with known prostate cancer. However, an elevated or rising PSA level does not automatically establish a new or recurrent malignancy.

R97.20 – Elevated PSA

R97.20 identifies an elevated prostate-specific antigen level.

Suppose a primary care physician identifies an elevated PSA during a routine evaluation. The patient has no confirmed prostate cancer diagnosis and undergoes additional testing.

In this case, R97.20 may be appropriate. Reporting C61 before the clinician establishes malignancy would misrepresent the patient’s documented condition.

R97.21 – Rising PSA Following Prostate Cancer Treatment

R97.21 identifies a rising PSA after treatment for malignant neoplasm of the prostate.

For example, a patient previously underwent radical prostatectomy, and subsequent laboratory results show rising PSA levels. The clinician evaluates the patient for possible biochemical recurrence.

R97.21 may help describe that clinical finding. However, a rising PSA value alone does not authorize the coder to report confirmed recurrent or metastatic cancer.

The provider must document the current disease status. If recurrence is confirmed, the appropriate malignancy code may also apply.

Additionally, C61 includes an instruction to use an additional code for rising PSA following treatment when applicable.

Follow-Up Care After Prostate Cancer Treatment

Patients often continue receiving medical surveillance long after surgery, radiation, or other cancer treatments.

Follow-up encounters help clinicians monitor for recurrence, review PSA trends, and assess the patient’s health after treatment.

Z08 – Follow-Up After Completed Cancer Treatment

Z08 represents an encounter for follow-up examination after completed treatment for malignant neoplasm.

When a patient has finished treatment, has no evidence of current cancer, and returns for routine cancer surveillance, the coding combination may include:

• Z08: Encounter for follow-up examination after completed treatment for malignant neoplasm.

• Z85.46: Personal history of malignant neoplasm of prostate.

For qualifying routine surveillance encounters, Z08 generally precedes Z85.46.

However, a visit for treatment complications, a new symptom, or suspected recurrence may require a different code selection and sequence.

Prostate Cancer Documentation Requirements for Accurate ICD-10 Coding

Even when a provider establishes the correct diagnosis, incomplete documentation can create uncertainty for the coding team.

A well-documented encounter should explain the patient’s current cancer status, treatment, and reason for receiving care.

Confirm the Current Diagnosis

The provider’s assessment should establish whether the patient has active prostate cancer, a previously treated malignancy, or an abnormal finding that requires further investigation.

Terms such as history of prostate cancer, active disease, biochemical recurrence, and metastatic prostate cancer have different coding implications.

Identify the Disease Location

When cancer extends beyond the prostate, providers should identify the affected anatomical sites.

For example, documentation stating “metastatic prostate cancer involving pelvic lymph nodes and lumbar spine” gives the coding team more useful information than a vague statement such as “advanced cancer.”

Document Hormone Sensitivity

The medical record should identify hormone-sensitive or castration-resistant disease when the clinician has established that status.

This helps billing teams determine whether an additional code from category Z19 applies.

Clarify the Treatment Status

Providers should document whether the patient is receiving active cancer treatment, undergoing surveillance, completing postoperative management, or attending a routine follow-up examination.

A patient who recently completed surgery may still receive treatment directed at the primary malignancy. Therefore, the treatment timeline matters when deciding between C61 and Z85.46.

Record the Reason for Each Encounter

The first-listed diagnosis should reflect the services provided during the encounter, subject to applicable coding and sequencing guidelines.

For instance, a chemotherapy administration visit differs from an oncology consultation, even when both encounters involve the same underlying malignancy.

Common Prostate Cancer ICD-10 Coding Mistakes

Small coding mistakes can lead to unnecessary claim corrections, delayed processing, or additional documentation requests. Recognizing common errors helps healthcare practices improve coding consistency.

1. Reporting C61 for Every Patient With a Cancer History

A prior prostate cancer diagnosis does not automatically justify using C61 indefinitely.

When treatment is complete and the primary malignancy no longer exists, Z85.46 may better reflect the documented condition.

2. Coding Prostate Cancer From an Elevated PSA Alone

An elevated PSA does not confirm prostate cancer. Other prostate conditions may also affect PSA levels.

Providers must establish the cancer diagnosis before coders assign C61.

3. Ignoring Metastatic Disease

When the clinician documents cancer involving bones, lymph nodes, or other secondary sites, the coding team should evaluate whether additional malignant neoplasm codes are necessary.

Failing to capture documented metastatic disease can leave the diagnosis information incomplete.

4. Incorrectly Sequencing Treatment Encounters

Placing C61 first on every oncology claim overlooks specific sequencing rules for chemotherapy, immunotherapy, and radiation encounters.

Medical billing teams should review the reason for the appointment before finalizing diagnosis sequencing.

5. Assuming Biochemical Recurrence Automatically Means Confirmed Cancer Recurrence

A rising PSA following treatment may raise clinical concern, but coders must not independently diagnose recurrent cancer from laboratory results.

If the medical record does not clearly establish the diagnosis, the provider may need to clarify the assessment.

6. Missing Hormone Sensitivity Documentation

Hormone-sensitive and castration-resistant disease can have different clinical implications.

When documented, the appropriate Z19 status code helps describe the malignancy more completely.

Practical Prostate Cancer Coding Examples

The following examples show how diagnosis coding changes according to the clinical circumstances.

These examples illustrate potential code combinations rather than universal claim sequences. The provider’s final diagnosis, treatment purpose, applicable Tabular List notes, and coding setting determine the correct reporting approach.

How Accurate Prostate Cancer Coding Supports Medical Billing

Prostate cancer claims can involve consultations, surgical services, laboratory testing, imaging, medication administration, and long-term surveillance. Each service creates opportunities for coding discrepancies when clinical documentation and billing workflows do not align.

Accurate diagnosis reporting helps practices establish a clearer connection between the documented condition and the services performed.

Reduce Avoidable Claim Errors

A careful review of ICD-10-CM codes helps billing teams identify outdated diagnoses, unsupported code combinations, and sequencing problems before submitting claims.

Although accurate coding does not guarantee reimbursement, it helps reduce preventable administrative work.

Improve Documentation Consistency

Prostate cancer patients often receive care from several specialists, including urologists, oncologists, radiologists, and primary care providers.

Consistent documentation makes it easier for billing teams to identify the current diagnosis and treatment purpose across different encounters.

Strengthen Denial Management

When a payer questions a prostate cancer claim, billing staff need to determine whether the issue involves diagnosis coding, medical necessity, authorization, coverage limitations, or another claim requirement.

Reviewing the clinical record and payer policy helps the team identify the appropriate corrective action.

Support Revenue Cycle Management

Organized coding workflows help medical practices manage the administrative complexities of oncology billing.

Vermont Medical Billing supports healthcare providers with medical coding, claims management, and revenue cycle processes that require attention to clinical documentation and payer requirements.

Best Practices for Prostate Cancer Medical Coding in 2027

Healthcare practices can improve coding accuracy by integrating a few essential checks into their existing claim preparation workflows.

1. Verify the current diagnosis. Determine whether the patient has active prostate cancer, a history of treated cancer, or an unconfirmed clinical finding.

2. Review metastatic involvement. Identify additional malignant neoplasm codes when the clinician documents confirmed secondary disease.

3. Check the treatment status. Determine whether the encounter involves active cancer treatment, surveillance, or another service.

4. Apply the correct sequencing rules. Follow ICD-10-CM instructions for primary cancer, metastatic disease, and treatment administration.

5. Confirm supporting documentation. Review the provider’s assessment before assigning hormone sensitivity or recurrence-related codes.

6. Use the current code set. Apply the ICD-10-CM release corresponding to the patient’s date of service.

7. Review payer-specific requirements. Confirm medical necessity, authorization, and billing requirements without assuming that a valid diagnosis code guarantees coverage.

The Centers for Medicare & Medicaid Services (CMS) provides official ICD-10-CM resources, including annual coding updates and guidelines. Healthcare organizations should use these resources alongside payer policies and relevant documentation standards.

Frequently Asked Questions About Prostate Cancer ICD-10 Codes

What is the ICD-10 code for prostate cancer?

The ICD-10-CM code for current primary prostate cancer is C61, Malignant neoplasm of prostate. It applies when the healthcare provider documents an established malignancy originating in the prostate.

What is the ICD-10 code for a history of prostate cancer?

Z85.46 identifies a personal history of malignant neoplasm of the prostate. It generally applies when the primary cancer has been eradicated, no evidence of existing primary disease remains, and treatment directed at that site has ended.

What is the ICD-10 code for metastatic prostate cancer?

There is no single ICD-10-CM code that captures every form of metastatic prostate cancer. C61 identifies the primary prostate malignancy, while additional codes describe confirmed metastatic sites. For example, C79.51 identifies secondary malignant neoplasm of bone.

What is the ICD-10 code for prostate cancer with bone metastases?

C79.51 identifies secondary malignant neoplasm of bone. When a patient has active primary prostate cancer with bone metastases, both C61 and C79.51 may apply, depending on the documented encounter.

What is the ICD-10 code for prostate cancer in remission?

ICD-10-CM does not provide a separate general remission code for prostate cancer. Code selection depends on whether the malignancy remains current, whether treatment continues, and whether the patient meets the criteria for a personal history code.

What is the ICD-10 code for castration-resistant prostate cancer?

C61 identifies the primary prostate malignancy, while Z19.2 identifies hormone-resistant malignancy status. These codes may be reported together when the provider documents active prostate cancer with castration-resistant status.

Can a patient have both C61 and Z85.46?

A current primary prostate malignancy and a history code for the same eradicated primary site generally should not be reported together as if both statuses apply simultaneously. However, patients with a previously eradicated primary tumor and current metastases may require a metastatic neoplasm code alongside Z85.46.

What is the ICD-10 code for elevated PSA without prostate cancer?

R97.20 identifies elevated prostate-specific antigen. Healthcare providers should not use C61 solely because a patient’s PSA result is above the reference range.

What ICD-10 codes apply after prostatectomy?

The appropriate diagnosis codes depend on whether the patient has active malignancy, receives further treatment, or attends surveillance after completed treatment. C61, Z85.46, and Z08 may apply in different situations, depending on the provider’s documentation and encounter purpose.

Final Thoughts

Selecting the appropriate ICD-10 code for prostate cancer requires more than identifying C61 in the codebook. Healthcare providers and medical billing teams must consider whether the malignancy remains active, whether treatment has been completed, and whether cancer has spread to additional anatomical sites.

Accurate coding also depends on clear documentation, appropriate diagnosis sequencing, and consistent application of the current ICD-10-CM guidelines. By addressing these factors before claim submission, medical practices can reduce unnecessary corrections and maintain more reliable billing workflows.

For healthcare organizations looking to strengthen medical coding, denial management, and claims processing, Vermont Medical Billing can serve as a medical billing resource for managing complex documentation and reimbursement workflows.